SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Zwiener who wrote (13)12/11/1996 2:33:00 AM
From: John Zwiener   of 1115
 
Continued.............
5) Why didn't Lidak design the original phase 3 study to
concentrate more on the prevention properties of Lidakol when
applied during the prodromal (preblister) phase of a herpes outbreak?
A: Because the primary endpoints for approval were a decrease
in duration. Preventing or aborting an attack were 2ndary endpoints.

6) Don't you realize that one of the best selling points would be
prevention?
A: Yes, the new study should get more data on this. But you have
to realize that in these studies that a patient has to get to the clinic
during the prodromal phase to get counted. Few people make it in
time. (The phase 3 study prevented 75% of attacks vs 13% without
the drug vs 50% with the placebo)

7) This is a great story. It seems to hold together. But after all
that's happened, why should I believe this stuff?
A: I've been specific. I better be telling the truth. I don't want to
go to jail.

8) Why do you think the price of the stock is going up?
A: I don't know, but 18? companies have visited or have been
visited by us. Maybe there is interest. I don't know, but I'd like to
think that they are interested.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext